Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis

Hepatic fibrosis: A convergent response to liver injury that is reversible

(2020) Shuang Wang et al.   JOURNAL OF HEPATOLOGY

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

(2020) Natascha Roehlen et al.   Cells

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis

(2020) Yuki Tsuji et al.   Microorganisms

Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades

(2019) Taisuke Hoshi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases

(2019) Feng Liu et al.   CLINICAL SCIENCE

A global view of hepatocellular carcinoma: trends, risk, prevention and management

(2019) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

(2019) Elena De Mattia et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo

(2019) SACHIKO OGASAWARA et al.   ANTICANCER RESEARCH

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

(2018) Masahiro Matsuki et al.   Cancer Medicine

The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis

(2018) Zhuo Wang et al.   LABORATORY INVESTIGATION

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model

(2018) Takayuki Kimura et al.   CANCER SCIENCE

Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice

(2018) Beom Jin Lim et al.   Cell Communication and Signaling

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

(2017) Kosuke Kaji et al.   INTERNATIONAL JOURNAL OF CANCER

Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling

(2017) Misako Sato-Matsubara et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Liver sinusoidal endothelial cells: Physiology and role in liver diseases

(2017) Johanne Poisson et al.   JOURNAL OF HEPATOLOGY

Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice

(2017) Ling-Jian Kong et al.   Molecular Medicine Reports

Mechanisms of hepatic stellate cell activation

(2017) Takuma Tsuchida et al.   Nature Reviews Gastroenterology & Hepatology

Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B

(2016) Jiyuan Zhou et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

(2016) Kai Qu et al.   Oncotarget

Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors

(2016) Justin D. Schumacher et al.   Biomed Research International

Pathobiology of liver fibrosis: a translational success story

(2015) Youngmin A Lee et al.   GUT

CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism

(2015) Annika Wilhelm et al.   GUT

Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of Delta-like1

(2015) Ruo-Lang Pan et al.   HEPATOLOGY

PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors

(2014) Chunsheng Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats

(2014) Laura Coch et al.   HEPATOLOGY

Liver cirrhosis

(2014) Emmanuel A Tsochatzis et al.   LANCET

Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

(2014) Ikuo Nakamura et al.   PLoS One

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib

(2013) Yan-Ru Deng et al.   JOURNAL OF AUTOIMMUNITY

Peroxisome proliferator-activated receptor-  interrupts angiogenic signal transduction by transrepression of platelet-derived growth factor-  receptor in hepatic stellate cells

(2013) F. Zhang et al.   JOURNAL OF CELL SCIENCE

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis

(2012) Keiko Iwaisako et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Functional aspects on the pathophysiology of portal hypertension in cirrhosis

(2012) Juan-Carlos García-Pagán et al.   JOURNAL OF HEPATOLOGY

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study

(2011) M. Pinter et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats

(2011) Nan Lin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells

(2011) Sara Aleffi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Mechanisms of hepatic fibrogenesis

(2011) Ursula E. Lee et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib

(2011) Yuqing Liu et al.   JOURNAL OF HEPATOLOGY

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

(2011) Romain Coriat et al.   PLoS One

The role of hypercoagulability in liver fibrogenesis

(2011) Quentin M. Anstee et al.   Clinics and Research in Hepatology and Gastroenterology

New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis

(2010) Yan Wang et al.   JOURNAL OF HEPATOLOGY

Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases

(2010) Claudia Paternostro   WORLD JOURNAL OF GASTROENTEROLOGY